MAY 2 3 2001 E

RECEIVED
MAY 2 5 2001

P19771.P08

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sususmu SEINO et al.

Serial No.: 09/617,099

Group Art Unit: 1645

Filed :

July 14, 2000

Examiner

: Not yet known

For

PROTEIN RIM2

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents and Trademarks Washington, DC 20231

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant hereby brings the following information, which information was cited in a European Search Report (submitted herewith in English) issued in connection with European Application No. EP 00 11 6148. The Examiner is referred to the European Search Report for an indication of the relevance given by the European Examiner to the cited documents relative to the claims of the European application.

Wang, Y., et al., Rim is a putative Rab3 effector in regulating synaptic-vesuicle fusion, Nature, Vol. 388, 593-598 (1997).

Database Swall 'Online!', Andersson, B., et al., *Hypothetical 41.8 Kda Protein (Fragment)*, retrieved from EBI, Database accession no. 043413 (1998).

Database EMBL 'Online!', Ohara, O., et al., Homo Sapiens mRNA for KIAA0751 protein, complete cds, retrieved from EBI, Accession no. AB018294 (1998).

Ozaki, N., et al., *cAMP-GEFII* is a direct target of *cAMP* in regulated exocytosis, Nature Cell Biology, Vol. 2, 805-811 (2000).

Wang, Y., et al., *The RIM/NIM Family of Neuronal C2 Domain Proteins*, JBC, Vol. 275, No. 26, 20033-20044 (2000).

Copies of the above-noted documents are enclosed together with a duly completed form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicant respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

In accordance with 37 C.F.R. 1.97(e), the undersigned hereby states that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Of course, this statement does not apply to information that has previously been cited by Applicant or the Examiner in the present application as that information is already of record and no certification is necessary.

Should the Examiner have any questions or comments regarding this matter, the undersigned

may be contacted at the below-listed telephone number.

RECEIVED

Respectfully submitted, Sususmu SEINO et al.

MAY 2 5 2001

TECH CENTER 1600/2900

Bruce H. Bernstein

Reg. No. 29,027

31,296

May 21, 2001 GREENBLUM & BERNSTEIN, P.L.C. 1941 Roland Clarke Place Reston, VA 20191 (703) 716-1191